Endotracheal tubes are the principal means by which anesthesia and oxygen are administered to patients during intubation. There are approximately 20 million endotracheal tubes sold within the US and 30 million in the rest of the world¹. Market annual growth is estimated to be 5.5%². Approximately 85% of intubations occur during non-emergency surgery and 15% are in the emergency room or ICU³.

Pneumonia is the most common nosocomial infection among ICU patients and is often associated with mechanical ventilation. Ventilator-associated pneumonia (VAP) is a matter of concern in many countries, including the United States.  Bacterial growth on endotracheal tubes is a key component in the pathogenesis of VAP which afflicts an estimated 250,000 patients each year and is associated with high morbidity (36,000 deaths). VAP extend ICU stays and are thereby very expensive. The per case cost is between $10,000 and $25,000 per case to manage Multiplying by the 250,000 cases per year yields a total US healthcare burden between $2.5 billion and $6.25 billion.

Enox believes, based on laboratory data, that a NO embedded endotracheal tube will outperform existing devices on the market costing $90 per unit. Enox believes that we can price our device at $100 per unit. The approachable market is the 15% of endotracheal tubes used in the ER and ICU where infection is of heightened concern and represents a $750 million opportunity.